Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Editas Medicine
ISIN US28106W1036
|WKN A2AC4K
Market cap (in EUR)
268 M
Country
États-Unis
Sector
Santé
Dividend yield
0,00%
Overview
Description
Editas Medicine, Inc. se consacre au développement et à la commercialisation de technologies d'édition du génome. Cette technologie comprend des répétitions palindromiques courtes et régulièrement espacées (CRISPR) et la protéine 9 associée à CRISPR (Cas9). La société a été fondée par Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung et David R. Liu en septembre 2013 et son siège social se trouve à Cambridge, MA.
Santé Produits biopharmaceutiques Produits biopharmaceutiques non systémiques États-Unis
Financials
Key metrics
| Market capitalisation, EUR | 268 M |
| EPS, EUR | -1,67 |
| P/B ratio | 11,5 |
| P/E ratio | - |
| Dividend yield | 0,00% |
Income statement (2025)
| Revenue, EUR | 36 M |
| Net income, EUR | -142 M |
| Profit margin | -395,01% |
What ETF is Editas Medicine in?
There is 1 ETF which contains Editas Medicine.
| ETF | Weight | Investment focus | Fund size (in m EUR) |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 0,02% | Equity United States Health Care Biotech | 46 |
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.